{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975668",
  "id": "02975668",
  "pages": 30,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0730",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdx0kbh3x5mq.pdf",
  "summary": "### **Summary of Material Information**  \n\n#### **Financial & Operational Highlights**  \n- **FY25 Revenue**: NZ$208.0M (6% YoY growth), with ANZ sales at NZ$180.9M.  \n- **FY25 Operating Profit**: NZ$17.6M (down from NZ$24.2M in FY24), impacted by lower license income (NZ$0.7M vs. NZ$8.5M) and 1H25 disruptions (Korean doctors\u2019 strike).  \n- **Dividend**: Increased to 1.8 cps (from 1.6 cps in FY24).  \n- **Net Debt**: Reduced to NZ$14.5M (from NZ$16.2M in FY24).  \n- **Cash Flow**: Closing cash balance not disclosed in extract; NZ EBITDA reconciliation shows NZ$20.9M for FY25.  \n\n#### **Growth Targets & Outlook**  \n- **Revenue Target**: NZ$300M by FY27.  \n- **FY26 Operating Profit Guidance**: NZ$20M\u2013NZ$24M.  \n\n#### **Key Developments**  \n- **International Expansion**:  \n  - Products sold in nearly **80 countries**; revenue from global partnerships declined to NZ$15.4M (vs. NZ$19.3M in FY24) due to destocking.  \n  - Launches in new markets (UK, EU, Canada, South Africa, Hong Kong, Singapore).  \n- **R&D Pipeline**:  \n  - **8 patented products** in active development, including Maxigesic IV (pediatric filing 3Q26), Crystaderm (antibacterial), and Pascomer (no approved treatment).  \n  - **24+ injectable products** under development.  \n  - R&D spend: NZ$15.0M (FY25).  \n\n#### **Governance**  \n- **Resolutions Passed**: Auditor remuneration, re-election of MD Hartley Atkinson, election of Allison Yorston (new independent director).  \n\n#### **Material Risks/Omissions**  \n- No explicit disclosure of **cash balance** or **capital structure changes** (e.g., issuance/buybacks).  \n- **Forward-looking statements** rely on commercialization success and market conditions.  \n\n**Format**: Concise bullets tailored for trading/capital markets decisions. Omitted non-material details (e.g., director bios, operational minutiae).",
  "usage": {
    "prompt_tokens": 5861,
    "completion_tokens": 500,
    "total_tokens": 6361,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T21:59:04.207955"
}